Grigoris T Gerotziafas
Overview
Explore the profile of Grigoris T Gerotziafas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
804
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gerotziafas G, Mahe I, Lefkou E, AboElnazar E, Abdel-Razeq H, Taher A, et al.
Thromb Res
. 2020 Aug;
191 Suppl 1:S50-S57.
PMID: 32736779
A B S T R A C T Important progress has been made in the development of risk assessment models (RAM) for the identification of outpatients on anticancer treatment at...
12.
AmraneDjedidi R, Rousseau A, Larsen A, Elalamy I, Van Dreden P, Gerotziafas G
Thromb Res
. 2020 Feb;
187:170-179.
PMID: 32006891
The endothelium could be a potential target of cancer cell derived extracellular vesicles (CaCe-dEV). We investigated in vitro the effect of CaCe-dEV on the hemostatic balance of endothelial cells. Extracellular...
13.
Mahe I, Elalamy I, Gerotziafas G, Girard P
TH Open
. 2019 Nov;
3(4):e348-e349.
PMID: 31696158
[This corrects the article DOI: 10.1055/s-0039-1696659.].
14.
Papageorgiou L, Alhaj Hussen K, Thouroude S, Mbemba E, Cost H, Garderet L, et al.
TH Open
. 2019 Nov;
3(4):e340-e347.
PMID: 31693008
Hypercoagulability is a common blood alteration in newly diagnosed chemotherapy naïve patients with multiple myeloma. The identification of the procoagulant potential of cancer cells, which is principally related to tissue...
15.
Mahe I, Elalamy I, Gerotziafas G, Girard P
TH Open
. 2019 Sep;
3(3):e309-e315.
PMID: 31535076
Direct oral anticoagulants (DOACs) represent an attractive alternative to low-molecular-weight heparins (LMWHs) for the long-term treatment of cancer-associated thrombosis (CT) since they avoid the burden of daily injections. Analyses in...
16.
Fotiou D, Sergentanis T, Papageorgiou L, Stamatelopoulos K, Gavriatopoulou M, Kastritis E, et al.
Blood Cancer J
. 2018 Nov;
8(11):102.
PMID: 30405097
Venous thromboembolism (VTE) is a common complication in newly diagnosed symptomatic multiple myeloma (NDMM) patients. We explored cellular and plasma hypercoagulability in NDMM patients to identify relevant biomarkers that can...
17.
Salta S, Papageorgiou L, Larsen A, Van Dreden P, Soulier C, Cokkinos D, et al.
Res Pract Thromb Haemost
. 2018 Oct;
2(4):696-707.
PMID: 30349889
Background: Venous thromboembolism (VTE) is associated with significant morbidity and mortality. Objectives: We investigated the impact of direct and AT-dependent FXa or thrombin inhibitors on thrombus formation. Methods: Whole blood...
18.
Papageorgiou C, Jourdi G, Adjambri E, Walborn A, Patel P, Fareed J, et al.
Clin Appl Thromb Hemost
. 2018 Oct;
24(9_suppl):8S-28S.
PMID: 30296833
Disseminated intravascular coagulation (DIC) is an acquired clinicobiological syndrome characterized by widespread activation of coagulation leading to fibrin deposition in the vasculature, organ dysfunction, consumption of clotting factors and platelets,...
19.
Syrigos K, Grapsa D, Sangare R, Evmorfiadis I, Larsen A, Van Dreden P, et al.
Oncologist
. 2018 Aug;
23(11):1372-1381.
PMID: 30104289
Background: The aim of this prospective study was to identify the most clinically relevant hypercoagulability biomarkers in lung adenocarcinoma patients for elaboration of an improved risk assessment model (RAM) for...
20.
Gerotziafas G, Papageorgiou L, Salta S, Nikolopoulou K, Elalamy I
Thromb Res
. 2018 Apr;
164 Suppl 1:S62-S69.
PMID: 29703486
Venous thromboembolism (VTE) occurring in hospitalized medical patients is associated with increased length of hospitalization, high rate of acute care hospital transfer, longer inpatient rehabilitation and multiplication of health-care costs....